Dublin, Oct. 19, 2016 -- Research and Markets has announced the addition of the "IV Fluid Transfer Drugs Devices and Markets" report to their offering.
Intravenous drug administration is one of the most common therapeutic procedures that patients in a hospital setting are likely to receive. Yet the lack of standardization among the various components, elements and steps that a caregiver must navigate to successfully execute a drug infusion have - according to several recent studies - contributed to medication errors and risks to patient safety.
IV drug administration was once provided to patients only in clinical settings. However, technology developments and a greater emphasis on cost containment over the last 30 years have prompted a shift to providing this therapy in alternate settings, including the home. IV fluid transfer drugs devices and markets is a detailed analysis of this evolving market.
What You Will Learn
- Analyzes and evaluates the global market for IV fluid transfer devices and assesses the probable impact of evolving regulatory, economic and demand factors
- Assesses approved IV fluid transfer devices and their market position
- Provides detailed descriptions of IV fluid transfer market segments and market factors
- Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners
- Evaluates the impact of economic, technology, and regulatory factors on IV drug administration
Key Topics Covered:
1. Executive Summary
2. IV Administration Market Dynamics
- Evolution in Patient Care
- Demand Drivers
- Competitive Landscape
- Factors Limiting Growth
3. IV Fluid Transfer Device Design Factors
- Reducing Medication Errors
- Lyophilization and Reconstitution
- Provider and Patient Wellbeing
4. Device Profiles and Analysis
- I.V. Containers
- Fluid Transfer Devices
- Reconstitution Devices
5. Market Analysis and Assessment
- Autoimmune
- Blood Disorders
- Cardiovascular
- Metabolic
- Neurology
- Oncology
6. Market Factors
- Regulatory Factors
- Managed Care Initiatives
7. Product Evolution and Wearable Infusion Devices
8. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/cnbzjg/iv_fluid_transfer
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables


U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Italy Fines Apple €98.6 Million Over App Store Dominance
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 



